Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
08 04 2023
Historique:
received: 09 06 2022
accepted: 27 03 2023
revised: 23 03 2023
medline: 11 4 2023
entrez: 8 4 2023
pubmed: 9 4 2023
Statut: epublish

Résumé

Grey matter pathology is central to the progression of multiple sclerosis (MS). We discovered that MS plasma immunoglobulin G (IgG) antibodies, mainly IgG1, form large aggregates (>100 nm) which are retained in the flow-through after binding to Protein A. Utilizing an annexin V live-cell apoptosis detection assay, we demonstrated six times higher levels of neuronal apoptosis induced by MS plasma IgG aggregates (n = 190, from two cohorts) compared to other neurological disorders (n = 116) and healthy donors (n = 44). MS IgG aggregate-mediated, complement-dependent neuronal apoptosis was evaluated in multiple model systems including primary human neurons, primary human astrocytes, neuroblastoma SH-SY5Y cells, and newborn mouse brain slices. Immunocytochemistry revealed the co-deposition of IgG, early and late complement activation products (C1q, C3b, and membrane attack complex C5b9), as well as active caspase 3 in treated neuronal cells. Furthermore, we found that MS plasma cytotoxic antibodies are not present in Protein G flow-through, nor in the paired plasma. The neuronal apoptosis can be inhibited by IgG depletion, disruption of IgG aggregates, pan-caspase inhibitor, and is completely abolished by digestion with IgG-cleaving enzyme IdeS. Transmission electron microscopy and nanoparticle tracking analysis revealed the sizes of MS IgG aggregates are greater than 100 nm. Our data support the pathological role of MS IgG antibodies and corroborate their connection to complement activation and axonal damage, suggesting that apoptosis may be a mechanism of neurodegeneration in MS.

Identifiants

pubmed: 37031195
doi: 10.1038/s41419-023-05783-3
pii: 10.1038/s41419-023-05783-3
pmc: PMC10082781
doi:

Substances chimiques

Immunoglobulin G 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

254

Subventions

Organisme : NIMH NIH HHS
ID : R21 MH118174
Pays : United States
Organisme : NIMH NIH HHS
ID : R33 MH118174
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States
Organisme : NINDS NIH HHS
ID : P30 NS048154
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK116073
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

J Neuroimmunol. 2000 Apr 3;104(1):58-67
pubmed: 10683515
Front Immunol. 2022 Jul 26;13:924734
pubmed: 35958570
Biochemistry. 2004 Dec 14;43(49):15540-9
pubmed: 15581366
Acta Neuropathol Commun. 2014 May 09;2:53
pubmed: 24887075
Brain. 2012 Jun;135(Pt 6):1819-33
pubmed: 22561643
Ann Neurol. 2001 Nov;50(5):646-57
pubmed: 11706971
AJNR Am J Neuroradiol. 2017 Jan;38(1):18-24
pubmed: 27686487
PLoS One. 2017 Oct 23;12(10):e0186842
pubmed: 29059249
J Neuroinflammation. 2016 Jun 22;13(1):161
pubmed: 27333900
J Neuroimmunol. 2017 Aug 15;309:88-99
pubmed: 28601295
Front Immunol. 2018 Jul 13;9:1590
pubmed: 30057580
Brain. 1997 Mar;120 ( Pt 3):393-9
pubmed: 9126051
Science. 2014 Mar 14;343(6176):1260-3
pubmed: 24626930
J Neuroimmunol. 2012 Jun 15;247(1-2):86-94
pubmed: 22531276
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):
pubmed: 33563762
N Engl J Med. 1998 Jan 29;338(5):278-85
pubmed: 9445407
Arch Neurol. 1986 Nov;43(11):1129-31
pubmed: 3778245
Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e200
pubmed: 26894204
PLoS One. 2020 Feb 21;15(2):e0228883
pubmed: 32084151
Neurology. 2018 Jun 12;90(24):e2107-e2118
pubmed: 29769373
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18697-702
pubmed: 17121989
Adv Immunol. 1992;51:1-84
pubmed: 1502974
Ann Neurol. 2004 Apr;55(4):458-68
pubmed: 15048884
Sci Rep. 2019 May 31;9(1):8147
pubmed: 31148572
Neurol Res. 2013 Nov;35(9):922-9
pubmed: 23845827
Brain Pathol. 1998 Oct;8(4):681-94
pubmed: 9804377
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 23;9(1):
pubmed: 34815322
J Neuroimmune Pharmacol. 2022 Jun;17(1-2):218-227
pubmed: 33942224
Clin Exp Immunol. 1982 Apr;48(1):102-10
pubmed: 7083640
J Neurol Neurosurg Psychiatry. 2009 Mar;80(3):292-6
pubmed: 18829628
J Immunol. 1997 Aug 15;159(4):1718-27
pubmed: 9257833
Neurology. 1980 Mar;30(3):240-4
pubmed: 7189023
Brain. 2018 Jun 1;141(6):1665-1677
pubmed: 29741648
Mult Scler. 2012 Oct;18(10):1401-11
pubmed: 22354735
Sci Rep. 2021 Jul 22;11(1):14987
pubmed: 34294805
J Immunol. 2016 Sep 1;197(5):1762-75
pubmed: 27474078
Biophys J. 2003 Jan;84(1):509-22
pubmed: 12524303
Int J Mol Sci. 2022 Jul 08;23(14):
pubmed: 35886931
Nature. 2021 Sep;597(7878):709-714
pubmed: 34497421
J Cell Sci. 2000 Apr;113 ( Pt 7):1277-85
pubmed: 10704378
J Neurosci. 2001 Aug 15;21(16):6214-20
pubmed: 11487644
J Pharm Sci. 2015 Feb;104(2):750-9
pubmed: 25231267
Nature. 2020 Dec;588(7838):485-490
pubmed: 33032297
Lancet Neurol. 2015 Feb;14(2):183-93
pubmed: 25772897
PLoS One. 2014 Mar 31;9(3):e92872
pubmed: 24686948
Mol Immunol. 2017 Dec;92:28-37
pubmed: 29031045
Adv Immunol. 1982;32:157-252
pubmed: 7051784
Acta Neuropathol. 2021 Apr;141(4):585-604
pubmed: 33569629
Acta Neurol Scand. 1967;43(S31):180-1
pubmed: 4171039
Ann Neurol. 2000 Jun;47(6):707-17
pubmed: 10852536
J Immunol. 2002 Jan 1;168(1):458-65
pubmed: 11751993
Front Neurol. 2020 Oct 20;11:533388
pubmed: 33192968
Ann Neurol. 2008 Jan;63(1):16-25
pubmed: 18232012
Nature. 2019 Sep;573(7772):75-82
pubmed: 31316211
J Neuroimmune Pharmacol. 2022 Dec;17(3-4):526-537
pubmed: 34989971
J Neuroimaging. 2017 Sep;27(5):476-480
pubmed: 28371088
Brain Pathol. 2022 Sep;32(5):e13054
pubmed: 35132719
Brain Res. 1971 May 21;28(3):365-90
pubmed: 4939243
Ann Clin Transl Neurol. 2016 Feb 01;3(3):166-79
pubmed: 27042677
J Neurochem. 2002 Apr;81(1):203-6
pubmed: 12067234
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7864-9
pubmed: 27325759
Neurosci Lett. 1998 Oct 16;255(2):75-8
pubmed: 9835218

Auteurs

Wenbo Zhou (W)

Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Michael Graner (M)

Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Petr Paucek (P)

Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Cheryl Beseler (C)

Department of Environmental, Agricultural and Occupational Health, University of Nebraska Medical Center, Omaha, NE, 68198, USA.

Matthew Boisen (M)

Zalgen Labs, LLC, 12635 E. Montview Blvd., Suite 131, Aurora, Colorado, 80045, USA.

Andrew Bubak (A)

Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Francisco Asturias (F)

Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Woro George (W)

Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Arin Graner (A)

Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

David Ormond (D)

Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Timothy Vollmer (T)

Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Enrique Alvarez (E)

Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA.

Xiaoli Yu (X)

Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA. Xiaoli.yu@cuanschutz.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH